Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Home
/
update
/
details

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

NextEdge Admin

07 Jan 2025

1 min 28 sec

Memorial Sloan Kettering Cancer Center,OncoKB™,NGS

Pillar Biosciences, Inc. has entered a strategic five-year licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to integrate OncoKB™, the first FDA-recognized somatic human variant database, into its PiVAT® bioinformatics platform. OncoKB™ provides crucial insights into the biological effects and treatment implications of specific cancer gene alterations, enhancing genomic reporting for oncology patients.

PiVAT® was designed to work seamlessly with Pillar’s proprietary SLIMamp® chemistry, ensuring accurate genomic variant detection for research-use-only (RUO) and in-vitro diagnostic (IVD) products. The partnership enables streamlined patient genomic reporting, removing bottlenecks in assay validation and implementation while facilitating rapid access to actionable insights.

Pillar Biosciences specializes in Decision Medicine™, utilizing advanced NGS technologies to optimize precision oncology, from tumor profiling to therapy selection and recurrence monitoring. With over 20 NGS testing kits in RUO and IVD formats, Pillar’s solutions aim to improve access, reduce costs, and enhance efficiency in cancer diagnostics worldwide.